InnoCan Pharma (IP40) AI Stock Analysis

6 Followers

InnoCan Pharma

(Frankfurt:IP40)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Strong Gross MarginsExceptionally high gross margins indicate favorable economics on products already sold and provide a substantial contribution pool for research, commercialization, and overhead. If maintained, this margin structure can support future operating leverage as revenue scales, even though profitability has not yet been achieved.

Negative Factors

Unprofitable OperationsInnoCan remains unprofitable at both the net and operating levels, while negative return on equity indicates that invested capital is not currently generating returns. Persistent losses can restrict internal funding for pharmaceutical development and make progress toward durable self-financing more difficult.

InnoCan Pharma (IP40) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 5.80M
Dividend Yield: ―
Average Volume (3M): 410
Price to Earnings (P/E): -6.2
Beta (1Y): -0.45
Revenue Growth: -23.91%
EPS Growth: 44.31%
Country: Germany
Employees: 11
Sector: Consumer Defensive
Sector Strength: 62
Industry: Medical - Pharmaceuticals

InnoCan Pharma Business Overview & Revenue Model

Company Description

InnoCan Pharma Corporation is a pharmaceutical enterprise dedicated to innovating drug delivery systems that integrate cannabidiol (CBD) with other pharmaceutical compounds. Its operations and development efforts span across the United States, Poland...

InnoCan Pharma Peers Comparison

Overall Rating

UnderperformOutperform

Sector (62)

Financial Indicators

DE:IP40 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	62Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
TSE:LABS	53Neutral	CAD 25.63M	-5.60	-13.79%	―	-6.74%	43.54%
TSE:VM	46Neutral	CAD 29.59M	-7.69	-193.11%	―	360.63%	14.21%
TSE:AVCN	44Neutral	CAD 13.44M	-2.62	-108.44%	―	-0.23%	-142.54%
TSE:ATLE	42Neutral	CAD 45.69M	-0.76	-2099.75%	―	-100.00%	94.43%

* Consumer Defensive Sector Average

Performance Comparison

DE:IP40 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:IP40	Innocan Pharma Corporation	1.03	-8.31	-88.93%
TSE:ATLE	Willow Biosciences	0.10	-0.07	-41.18%
TSE:LABS	Medipharm Labs (Otc)	0.07	-0.01	-7.14%
TSE:VM	Voyageur Pharmaceuticals Ltd.	0.13	-0.02	-13.33%
TSE:AVCN	Avicanna Inc	0.09	-0.17	-66.67%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

InnoCan Pharma AI Stock Analysis